Ardelyx Inc (ARDX) Stock Price, Quote & News

Company Profile

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in Ju...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 745 1700

Website: www.ardelyx.com

Address:

400 Fifth Avenue, Suite 210, Waltham, United States

mrbigstakes Feb. 24 at 2:39 AM

$ARDX nice

0 · Reply

Cusefan1000 Feb. 24 at 2:12 AM

$ARDX In Mott we trust!

1 · Reply

Cvong001 Feb. 24 at 2:04 AM

$ARDX

1 · Reply

findingthestock Feb. 24 at 1:57 AM

$ARDX WHY THE STOCK CAN DROP A LOT MORE -Q1 numbers will be bad, do not think it’s priced in. Stock will go down -A negative CMS outcome stock will drop a lot -challenges to patent

0 · Reply

mktfixer Feb. 24 at 1:33 AM

$ARDX where do you think we’d be trading if the analysts all came in bearish ? You know it’s an unequal playing field

0 · Reply

mktfixer Feb. 24 at 12:54 AM

$ARDX you know the market is spooked when they won't buy at $5.75 AH

0 · Reply

sandpiper633 Feb. 24 at 12:41 AM

$ARDX Tarsus, with less RD spend than ardelyx in Q4 reported a loss on $150MM revenue and sports a $3B market cap. $2B oeak sales with 2038 LOE. Ibsrela has entered the chat….folks here freaking out about opex spend are so minsformed.

1 · Reply

mktfixer Feb. 24 at 12:05 AM

$ARDX Ardelyx (ARDX) is currently considered undervalued based on recent analyses. The stock is trading at approximately $5.75 ,while its fair value is estimated at $13.50, suggesting a significant discount in valuation. A DCF analysis indicates that Ardelyx is undervalued by 88.6%, with projected free cash flow estimates showing strong growth potential. The stock has seen a recent decline, but its historical performance and strong earnings growth suggest it may be a good investment opportunity. Overall, the consensus among analysts is that Ardelyx's valuation is currently low, and it may be a good time to consider it as an investment. AGREE

0 · Reply

JazzyJ03 Feb. 23 at 11:59 PM

$ARDX

0 · Reply

TheYoungGeologist Feb. 23 at 11:00 PM

$ARDX at this point I don't mind if it stays down through summer again. I was impatient when I was waiting for this to fund my down payment, but now I have time

0 · Reply

Why Ardelyx's Offensive Strategy Doesn't Move The Needle

Feb 20, 2026, 11:12 AM EST - 3 days ago

Ardelyx: Strong IBSRELA Growth, But Heavy Operational Spend Clouds Profitability

Feb 20, 2026, 6:50 AM EST - 3 days ago

Ardelyx Lead Drug Growth Fails To Lift Sentiment, Stock Drops

Feb 20, 2026, 2:44 AM EST - 3 days ago

Ardelyx, Inc. (ARDX) Q4 2025 Earnings Call Transcript

Feb 19, 2026, 4:01 PM EST - 4 days ago

Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 5, 2026, 8:00 AM EST - 18 days ago

Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026

Feb 3, 2026, 8:29 AM EST - 20 days ago

Ardelyx Receives New Patent for Tenapanor

Jan 28, 2026, 8:29 AM EST - 26 days ago

First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA

Jan 21, 2026, 1:04 PM EST - 4 weeks ago

Ardelyx: Assessment Of Acquisition Rumors

Jan 20, 2026, 6:14 AM EST - 4 weeks ago

Ardelyx: IBSRELA Momentum Drives Opportunity

Jan 8, 2026, 8:30 AM EST - 6 weeks ago

Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook

Nov 7, 2025, 4:05 PM EST - 3 months ago

Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week

Nov 5, 2025, 8:00 AM EST - 3 months ago

Ardelyx to Participate at the Jefferies Global Healthcare Conference in London

Nov 5, 2025, 4:24 AM EST - 3 months ago

Ardelyx: Impressive Q3 Record Growth - Why I Buy

Nov 4, 2025, 3:32 PM EST - 3 months ago

Ardelyx: A Long Overdue Rally

Nov 4, 2025, 8:00 AM EST - 3 months ago

Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference

Oct 30, 2025, 11:06 PM EDT - 4 months ago

Ardelyx, Inc. (ARDX) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 4:01 PM EDT - 4 months ago

Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 28, 2025, 8:01 AM EDT - 4 months ago

Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology's 2025 Annual Meeting

Oct 21, 2025, 8:00 AM EDT - 4 months ago

Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology's Kidney Week

Oct 13, 2025, 8:35 AM EDT - 4 months ago

Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025

Oct 13, 2025, 8:30 AM EDT - 4 months ago

Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer

Sep 8, 2025, 10:11 AM EDT - 6 months ago

Ardelyx, Inc. (ARDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 3, 2025, 4:42 PM EDT - 6 months ago

Ardelyx, Inc. (ARDX) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 25, 2025, 8:00 AM EDT - 6 months ago

Ardelyx to Participate in Upcoming Investor Conferences

Aug 15, 2025, 6:17 AM EDT - 6 months ago

Ardelyx: Improved Outlook For Ibsrela And Xphozah

Aug 4, 2025, 8:11 PM EDT - 7 months ago

Ardelyx, Inc. (ARDX) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 4:08 PM EDT - 7 months ago

Ardelyx Announces Changes to the Executive Leadership Team

Aug 4, 2025, 4:01 PM EDT - 7 months ago

Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 21, 2025, 8:00 AM EDT - 7 months ago

Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025

Jun 2, 2025, 4:05 PM EDT - 9 months ago

Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer

May 21, 2025, 8:00 AM EDT - 9 months ago

Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025

May 6, 2025, 8:01 AM EDT - 10 months ago

Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference

May 2, 2025, 10:07 AM EDT - 10 months ago

Ardelyx: Revenue Misses And Losses Widen Amid XPHOZAH Uncertainty

May 1, 2025, 10:06 PM EDT - 10 months ago

Ardelyx, Inc. (ARDX) Q1 2025 Earnings Call Transcript

May 1, 2025, 4:01 PM EDT - 10 months ago

Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 29, 2025, 8:00 AM EDT - 10 months ago

Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

Apr 24, 2025, 8:01 AM EDT - 10 months ago

Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference

Apr 17, 2025, 8:00 AM EDT - 11 months ago

Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025

Apr 10, 2025, 4:02 PM EDT - 11 months ago

Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings

mrbigstakes Feb. 24 at 2:39 AM

$ARDX nice

0 · Reply

Cusefan1000 Feb. 24 at 2:12 AM

$ARDX In Mott we trust!

1 · Reply

Cvong001 Feb. 24 at 2:04 AM

$ARDX

1 · Reply

findingthestock Feb. 24 at 1:57 AM

$ARDX WHY THE STOCK CAN DROP A LOT MORE -Q1 numbers will be bad, do not think it’s priced in. Stock will go down -A negative CMS outcome stock will drop a lot -challenges to patent

0 · Reply

mktfixer Feb. 24 at 1:33 AM

$ARDX where do you think we’d be trading if the analysts all came in bearish ? You know it’s an unequal playing field

0 · Reply

mktfixer Feb. 24 at 12:54 AM

$ARDX you know the market is spooked when they won't buy at $5.75 AH

0 · Reply

sandpiper633 Feb. 24 at 12:41 AM

1 · Reply

mktfixer Feb. 24 at 12:05 AM

0 · Reply

JazzyJ03 Feb. 23 at 11:59 PM

$ARDX

0 · Reply

TheYoungGeologist Feb. 23 at 11:00 PM

$ARDX at this point I don't mind if it stays down through summer again. I was impatient when I was waiting for this to fund my down payment, but now I have time

0 · Reply

mktfixer Feb. 23 at 10:50 PM

$ARDX funny how this dries up AH and goes dead...totally driven during mkt reg hrs..

0 · Reply

mktfixer Feb. 23 at 10:28 PM

$ARDX now would be the time to make the move for BO for Zydus...the longer they hold off the higher the price to pay... I can't see this staying down too long...

2 · Reply

creamysoftserve Feb. 23 at 10:18 PM

$ARDX listened to the TARS call and they are also projecting a break even year (670-700m product revenues with 545-565 SGA and 115-135m R&D). truly wild to see how the market reacts to another break even guidance call. hopefully, we pick up again soon!

2 · Reply

bams1017 Feb. 23 at 10:00 PM

$ARDX Based on Piktoro's post - I just relistened to part of the call. I love Susan's response at 33:35. And then about a minute later she makes the slight comment of "stay tuned" regarding Cash Flow Positivity....and Raab does jump in and interrupt her. Great catch Piktoro! Now why would she make that comment?

1 · Reply

IMADORK Feb. 23 at 9:51 PM

$ARDX Perhaps reading too much into this. But, One wonders if all these leading Investment banks and Analysis-firms continually increasing their SP guidance on ArdX—some by substantial amounts, is a way of signaling ArdX management toward engaging a BO. Realistically, the only way ArdX could pop from current SP to $19 in one year, is a BO.

1 · Reply

Piktoro Feb. 23 at 9:08 PM

$ARDX Zydus wants to gain control of ARDX for $2.2 - 2.5 billion. Or buy a molecule. I think ARDX, given the renewal of patents and new research, will not want to sell control of the company. In a couple of years, the company can be sold for much more. The most acceptable option is to sell them the rights to Tenapanor (except the USA, Canada, Japan and China). For example, for 600,000 million dollars. I don't rule out that analysts are raising the stock price for a reason. The new CFO said they weren’t interested in positive cash flow right now, but said to keep an eye out for news from the company. Then Raab interrupted her.

6 · Reply

Chester_Copperpot85 Feb. 23 at 8:42 PM

$ARDX HC Wainwright initiated a $115 buy on ACLXin June, which was just bought out by Gilead for ....$115/sh. They just upgraded Ardy to $19 from $10. I trust their tribal knowledge.

2 · Reply

mktfixer Feb. 23 at 8:37 PM

$ARDX no expenses for growth allowed. You must be punished to hell

0 · Reply

mktfixer Feb. 23 at 8:34 PM

$ARDX hopefully we don't camp out here until April...

0 · Reply

jstnfstr Feb. 23 at 8:28 PM

$ARDX An XBI up 1.8 attempts to remain unfazed by a down-840 Dow, while Ardx manages to hold its own, near pre-Zydus levels. Would Zydus and Ardx be content with a 45% share ownership by the former with a stand-in-place agreement limiting ownership to 45% going forward, plus 50% board seats?

2 · Reply

MedHS55 Feb. 23 at 8:19 PM

$ARDX Hopefully we can end in the green. Biotech is having a decent day, but I'm concerned about margin calls going into the close.

0 · Reply

M_OF_E Feb. 23 at 7:16 PM

$ARDX Since the CC 8 analysts have reiterated their early Jan ratings, and 2 have raised their ratings HC Wainwright on Friday from 10 to 18 and Leerink today from 11 to 17

3 · Reply

Market Cap	1.39B
Revenue (ttm)	333.62M
Net Income (ttm)	-39.14M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	29.46
Profit Margin	-11.73%
Debt to Equity Ratio	1.31

Volume	7,057,300
Avg Vol	4,723,918
Day's Range	N/A - N/A
Shares Out	242.97M
Stochastic %K	7%
Beta	0.57
Analysts	Strong Sell
Price Target	$14.70